Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2/3. fázis

Low-dose Atropine for Myopia Control in Children

A legfontosabb adatok

Ki végzi
University Eye Hospital, Freiburg
Hol
Németország19 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
2/3. fázis
Résztvevők
302 fő vett részt
Kezdés
2021. okt. 19.
Várható befejezés
2027. nov.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Atropine eye drops, 0.01%
  • Atropine eye drops, 0.02%
  • Placebo (NaCl 0.9%) eye drops
A regiszteradat frissítve
2025. március 6.

Ki vehet részt

Életkor
8 év – 12 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female patients aged 8 to 12 years (up to the day before the 13th birthday)
  • Myopia of -1 D to -6 D with reported or documented annual progression ≥ 0.5 D of myopia
  • Written informed consent obtained from patient (if applicable) and parents or legal guardians according to international guidelines and local laws
  • Ability to understand the nature of the trial and the trial related procedures and to comply with them

Ki nem vehet részt

  • Previous use of any kind of contact lenses
  • Previous use of atropine eye drops
  • Participation in any other interventional clinical trial within the last 30 days before the start of this trial
  • History of amblyopia
  • Any acquired or developmental organic eye disease
  • Any known systemic metabolic disease or chromosomal anomaly
  • Epilepsy
  • Known hypersensitivity to the active substances or any of the excipients
  • Caution and pediatric counselling shall be assured if any of the following conditions are present according to the Summary of Product Characteristics (SmPC): Cardiac insufficiency, arrhythmia, coronary stenosis, hyperthyroidism, stomach or bowel stenosis, bowel paralysis, megacolon, muscle weakness, lung edema, hypersensitivity to atropine, spastic paralysis
  • Asian or African origin
  • Abnormal binocularity
  • Strabismus
  • Astigmatism >1.5 D
  • Anisometropia >1.5 D
  • Corrected visual acuity in any eye <0.63
  • Premature birth
  • Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registries and diagnostic trials is allowed
  • Contraindications according to the Summary of Product Characteristics (SmPC): Increased intraocular pressure (primary forms of glaucoma or narrow angle glaucoma), chronic rhinitis sicca
  • Parents or children with poor understanding of the German language
  • Person who is in a relationship of dependence/employment with the sponsor or the investigator

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Myopia (nearsightedness) is the most common eye disorder. Only second to age, it is the main risk factor for major degenerative eye diseases such as glaucoma, macular degeneration or retinal detachment. Their risk increases with the degree of myopia. Hence, prevention of myopia and slowing its progression is of high relevance. Almost all clinical studies, including two large randomised clinical trials (RCT) were performed in Asia with Asian study participants. The results indicate that atropine eye drops can attenuate myopic progression in children, even in low concentrations thus minimizing unwanted side effects. However, the cumulative evidence is yet not strong enough to recommend their unrestricted use, especially in a Non-Asian population. We therefore intend to set up an adequately powered RCT comparing atropine 0.02% eye drops with placebo to validate previous findings and to test whether this therapeutic concept holds its promise in a European population.

A vizsgálat 2 csoportja

  • Arm A, Interventional groupA vizsgált kezelés

    Treatment period 1: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 3: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months

    Kezelés: Atropine eye drops, 0.02% és Placebo (NaCl 0.9%) eye drops

  • Arm B, Control groupA vizsgált kezelés

    Treatment period 1: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months Treatment period 3: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months

    Kezelés: Atropine eye drops, 0.01% és Placebo (NaCl 0.9%) eye drops

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Low-dose Atropine for Myopia Control in Children, a Prospective, Double-blind, Placebo-controlled, Multicentric, Randomized Clinical Trial
Publikációk
A regiszteradat frissítve
2025. március 6.